Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series.
作者信息
Flach Johanna, Shumilov Evgenii, Porret Naomi, Shakhanova Inna, Legros Myriam, Kronig Marie-Noëlle, Joncourt Raphael, Bacher Ulrike, Pabst Thomas
机构信息
Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany.
出版信息
Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020068. doi: 10.4084/MJHID.2020.068. eCollection 2020.
Abstract
摘要
相似文献
1
Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series.复发急性髓系白血病的下一代测序经验：病例系列报告
Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020068. doi: 10.4084/MJHID.2020.068. eCollection 2020.
2
Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.下一代测序定义的干细胞移植前微小残留病可预测急性髓系白血病复发。
Am J Hematol. 2019 Aug;94(8):902-912. doi: 10.1002/ajh.25514. Epub 2019 Jun 14.
3
Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings.基于基因检测板的下一代测序有助于在临床环境中对儿童急性髓系白血病进行特征分析。
Biomed Rep. 2020 Nov;13(5):46. doi: 10.3892/br.2020.1353. Epub 2020 Aug 28.
4
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.下一代测序改善了髓系肿瘤的诊断、预后和临床管理。
Cancers (Basel). 2019 Sep 13;11(9):1364. doi: 10.3390/cancers11091364.
5
Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.基因突变作为复发急性髓系白血病新出现的生物标志物和治疗靶点
Front Pharmacol. 2017 Dec 7;8:897. doi: 10.3389/fphar.2017.00897. eCollection 2017.
6
Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.通过下一代测序探究急性髓系白血病的遗传图谱：大型癌症中心的经验
Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):121-126. doi: 10.21873/cgp.20070.
7
Next generation sequencing of acute myeloid leukemia: influencing prognosis.急性髓系白血病的下一代测序：对预后的影响
BMC Genomics. 2015;16 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2164-16-S1-S5. Epub 2015 Jan 15.
8
The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.下一代测序在急性髓系白血病和骨髓增生异常综合征诊断及监测中的应用。
Int J Lab Hematol. 2015 May;37 Suppl 1:115-21. doi: 10.1111/ijlh.12361.
9
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.急性髓系白血病中基于测序的可测量残留病检测
Front Cell Dev Biol. 2020 May 8;8:249. doi: 10.3389/fcell.2020.00249. eCollection 2020.
10
Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing.基于锚定多重PCR（AMP）的下一代测序技术检测复发难治性急性髓系白血病中的新型t(12;17)(p12;p13)
Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):e28-e31. doi: 10.1097/PAI.0000000000000477.
引用本文的文献
1
Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation.挽救性异基因干细胞移植在自体干细胞移植后复发的急性髓系白血病患者中的可行性和疗效
Bone Marrow Transplant. 2022 Feb;57(2):224-231. doi: 10.1038/s41409-021-01521-5. Epub 2021 Nov 13.
本文引用的文献
1
Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.在急性髓系白血病复发患者中引入下一代测序的临床潜力。
Hematol Oncol. 2020 Oct;38(4):425-431. doi: 10.1002/hon.2739. Epub 2020 May 6.
2
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
3
Clinical value of molecular MRD monitoring by next-generation sequencing in patients with mutated AML.下一代测序技术对突变型急性髓系白血病患者进行分子微小残留病监测的临床价值
Leuk Lymphoma. 2019 Oct;60(10):2588-2590. doi: 10.1080/10428194.2019.1585838. Epub 2019 Apr 18.
4
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.美国食品和药物管理局批准概要：ivosidenib 用于携带异柠檬酸脱氢酶-1 突变的复发性或难治性急性髓系白血病。
Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28.
5
Pitfalls in the molecular follow up of mutant acute myeloid leukemia.突变型急性髓系白血病分子随访中的陷阱
Haematologica. 2018 Oct;103(10):e486-e488. doi: 10.3324/haematol.2018.192104. Epub 2018 Jun 14.
6
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.治疗和复发期间细胞遗传学正常急性髓系白血病的演变：50 例患者的外显子组测序研究。
Clin Cancer Res. 2018 Apr 1;24(7):1716-1726. doi: 10.1158/1078-0432.CCR-17-2344. Epub 2018 Jan 12.
7
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.急性髓系白血病异体移植患者疾病复发的突变分析
Blood Adv. 2016 Dec 14;1(3):193-204. doi: 10.1182/bloodadvances.2016000760. eCollection 2016 Dec 27.
8
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
9
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.恩杂鲁胺用于治疗突变型复发或难治性急性髓系白血病。 （注：原文中药物名可能有误，推测正确药物名应该是Enasidenib为恩杂鲁胺，而这里治疗白血病的应该是Enasentinib，中文名为恩西地平 ，以下按照正确药物名给出译文）
恩西地平用于治疗突变型复发或难治性急性髓系白血病。
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
10
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
Zotero 插件